Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

27.20 -2.64 (-8.83%)

Delayed Quote Updated: 3:16 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Adaptive Biotechnologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday ↗

November 08, 2022

Gainers

Via Benzinga

Expert Ratings for Adaptive Biotechnologies ↗

November 07, 2022

Adaptive Biotechnologies (NASDAQ:ADPT) has observed the following analyst ratings within the last quarter:

Via Benzinga

Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed ↗

August 11, 2022

Via Benzinga

Adaptive Biotechnologies Clocks 26% Jump In Q4 Revenues ↗

February 16, 2022

Adaptive Biotechnologies Corp (NASDAQ: ADPT)

Via Benzinga

5 Top Stocks Cathie Wood Is Buying This Week ↗

November 04, 2022

Cathie Wood just lauded Elon Musk's acquisition of Twitter, believing the platform will become a "super-app." Here are her top five buys.

Via InvestorPlace

Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results

November 03, 2022

From Adaptive Biotechnologies

Via GlobeNewswire

General Electric To Surge Around 27%? Plus This Analyst Predicts $44 For General Motors ↗

October 26, 2022

RBC Capital raised the price target on General Electric Company (NYSE: GE) from $81 to $93. General Electric shares fell 0.5% to close at $73.00 on Tuesday.

Via Benzinga

Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers

October 11, 2022

Integration with the most widely used comprehensive electronic health record will expand clinician and patient access to clonoSEQ

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022

October 05, 2022

From Adaptive Biotechnologies

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗

August 25, 2022

Upgrades

Via Benzinga

Adaptive Biotechnologies: Q2 Earnings Insights ↗

August 03, 2022

Adaptive Biotechnologies (NASDAQ:ADPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Outlook For Adaptive Biotechnologies ↗

August 02, 2022

Adaptive Biotechnologies (NASDAQ:ADPT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Why Adaptive Biotechnologies Shares Are Rising ↗

June 15, 2022

Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares are trading higher by 12.58% to $7.25 after the company launched T-Detect Lyme, to help diagnose early lyme disease.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗

June 03, 2022

Via Benzinga

Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed ↗

May 23, 2022

Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $38.62 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 2.35%, resulting in a loss of $62.80...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 23, 2022

Gainers Creative Medical Tech (NASDAQ:CELZ) shares rose 78.8% to $3.04 during Wednesday's pre-market session. The market value of their outstanding shares is at $19.2...

Via Benzinga

Adaptive Biotechnologies To Lay Off ~12% Of Its Workforce, Names Tycho Peterson As CFO ↗

March 09, 2022

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) will be organized around two distinct business areas - Minimal Residual Disease (MRD) and Immune Medicine. Adaptive's...

Via Benzinga

Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed ↗

February 16, 2022

Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $37.93 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 9.57%, resulting in a loss of $61.36...

Via Benzinga

Recap: Adaptive Biotechnologies Q4 Earnings ↗

February 15, 2022

Adaptive Biotechnologies (NASDAQ:ADPT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics ↗

February 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...

Via Benzinga

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗

February 13, 2022

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...

Via Benzinga

12 Publicly Traded Companies On Fast Company's 'Next Big Things In Tech' List ↗

December 01, 2021

Real-world problem solvers are highlighted in the inaugural “Next Big Things In Tech” list by Fast Company. The list included 65 honorees from big companies to start-...

Via Benzinga

Earnings Scheduled For February 15, 2022 ↗

February 15, 2022

Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion.

Via Benzinga

Cathie Wood Goes Bargain Shopping -- 3 Troubled Stocks She Just Bought ↗

November 29, 2021

The internet's favorite stock picker has been very busy.

Via The Motley Fool

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares ↗

November 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...

Via Benzinga

Adaptive Biotechnologies Corporation (ADPT) Q3 2021 Earnings Call Transcript ↗

November 04, 2021

ADPT earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs ↗

October 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas...

Via Benzinga

Return on Capital Employed Insights for Adaptive Biotechnologies ↗

August 20, 2021

After pulling data from Benzinga Pro it seems like during Q2, Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $38.51 million. However, earnings decreased 20.55%,...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.